A detailed history of Jacobs Levy Equity Management, Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 476,949 shares of ALDX stock, worth $2.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
476,949
Previous 181,085 163.38%
Holding current value
$2.29 Million
Previous $599,000 329.05%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $6.32 $943,806 - $1.87 Million
295,864 Added 163.38%
476,949 $2.57 Million
Q2 2024

Aug 14, 2024

BUY
$3.25 - $4.72 $7,039 - $10,223
2,166 Added 1.21%
181,085 $599,000
Q1 2024

May 15, 2024

BUY
$2.77 - $4.22 $495,605 - $755,038
178,919 New
178,919 $585,000
Q4 2022

Feb 14, 2023

SELL
$5.08 - $7.09 $1.32 Million - $1.85 Million
-260,462 Reduced 92.42%
21,374 $148,000
Q3 2022

Nov 15, 2022

BUY
$3.8 - $7.74 $179,230 - $365,064
47,166 Added 20.1%
281,836 $1.51 Million
Q2 2022

Aug 15, 2022

BUY
$2.43 - $4.85 $570,248 - $1.14 Million
234,670 New
234,670 $936,000
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $341,967 - $487,110
-43,069 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$6.53 - $14.42 $1.66 Million - $3.67 Million
-254,763 Reduced 85.54%
43,069 $512,000
Q4 2020

Feb 16, 2021

SELL
$6.31 - $8.13 $50,492 - $65,056
-8,002 Reduced 2.62%
297,832 $2.04 Million
Q3 2020

Nov 16, 2020

BUY
$4.0 - $7.53 $3,180 - $5,986
795 Added 0.26%
305,834 $2.27 Million
Q2 2020

Aug 17, 2020

BUY
$1.97 - $5.05 $512,349 - $1.31 Million
260,076 Added 578.42%
305,039 $1.27 Million
Q1 2020

May 15, 2020

BUY
$1.62 - $6.4 $27,752 - $109,638
17,131 Added 61.55%
44,963 $111,000
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $131,645 - $222,099
27,832 New
27,832 $162,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $281M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.